Studies exploring the efficacy of immunotherapy in combination with MEK inhibitors or chemotherapy did not find a clear advantage in efficacy and safety compared with chemotherapy combined with targeted drugs in MSS tumors [22, 24]. This evidence concerns the gene MAP2K7 and Marinesco-Sjogren syndrome.